Acute Lymphoblastic Leukaemias (ALL) Recruiting Phase 2 Trials for Mercaptopurine (DB01033)

Also known as: Acute Lymphoblastic Leukemias / Acute Leukemia, Lymphoblastic / Acute Lymphoblastic Leukaemia / Acute Lymphoblastic Leukemia / Leukemia, Lymphoblastic, Acute / Lymphoblastic Leukemia, Acute / Leukemia, Acute Lymphoblastic / Leukaemia, Lymphoblastic, Acute / Acute Lymphoblastic Leukemia (ALL) / Leukemia, Lymphoblastic,Acute / Acute Leukaemia, Lymphoblastic / Acute lymphoblastic leukemia with failed remission / Leukemia lymphoblastic acute / Lymphoid leukaemia, acute / Acute lymphoid leukaemia / Lymphoid leukemia, acute / Acute lymphoid leukemia / ALL / Leukaemia lymphoblastic acute / Acute lymphocytic leukemia / Acute lymphatic leukaemia / Leukaemias acute lymphocytic / Acute lymphatic leukemia / Acute lymphocytic leukaemia

IndicationStatusPhase
DBCOND0073466 (Acute Lymphoblastic Leukaemias (ALL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02143414Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaTreatment
NCT02877303Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic LeukemiaTreatment
NCT03286634ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016Treatment
NCT00501826Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic LymphomaTreatment